InSite Vision to Present Five Scientific Posters at 2013 ARVO Meeting

Business Wirevia The Motley Fool
Updated

InSite Vision to Present Five Scientific Posters at 2013 ARVO Meeting

ALAMEDA, Calif.--(BUSINESS WIRE)-- InSite Vision Incorporated (OTCBB: INSV) today announced that it has sponsored research being presented in five scientific posters at the 2013 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting being held from May 5-9, 2013, in Seattle, Washington. The presentations cover data generated from the company's clinical programs for the treatment of blepharitis and ocular pain and inflammation, multiple preclinical candidates and InSite's DuraSite 2 platform technology.

Sunday, May 5, 2013

  • "Ocular pharmacokinetics of 0.2% and 0.4% ketorolac tromethamine formulated in DuraSite® or DuraSite® 2 delivery systems compared to Acular LS® in rabbits" (Poster #116-C0121) will be presented during the Inflammation and Drugs poster session from 8:30 am-10:15 am by Afshin Shafiee, Ph.D., Director, Preclinical R&D, of InSite Vision.

  • From 1:00 pm-2:45 pm, Lyle Bowman, Ph.D., Vice President, Development of InSite Vision, will present Poster #765-A0100 "Ocular pharmacokinetics of ISV-215 (Bimatoprost 0.03%) formulated in a DuraSite delivery system compared to Lumigan® in rabbits during the Pharmacological Interventions; Cellular Mechanisms; Electrophysiology session.

  • Judith Hutcheson, Director, Clinical Affairs of InSite Vision, will present "Safety of DuraSite vehicle as part of a topical treatment in cataract surgery patients" (Poster #1093-C0070) during the Drug Delivery I session from 1:00 pm-2:45 pm.


Tuesday, May 6, 2013

  • "Developing a questionnaire to measure the quality of life of blepharitis patients" (Poster #5318-D0079) will be presented by Linda Bourque, Ph.D., of the University of California at Los Angeles School of Public Health in collaboration with InSite Vision, during the Vision Function and Quality of Life session from 11:00 am-12:45 pm.

Wednesday, May 8, 2013

  • InSite Vision's Kamran Hosseini, M.D., Ph.D, Chief Medical Officer, V.P. Clinical & Regulatory Affairs, will present "Aqueous humor concentration of bromfenac 0.09% (Bromday®) compared with bromfenac in DuraSite® 0.075% (BromSite™) in cataract patients undergoing phacoemulsification after three-day dosing" (Poster #5061-B0019), during the Drug Delivery III session from 2:45 pm-4:30 pm.

About DuraSite®and DuraSite®2

While eye drops are a proven delivery mechanism for numerous ocular drugs, efficacy of these agents is impeded by tears and blinking, which rinse the drug from the surface of the eye and limit retention and absorption. InSite's DuraSite and DuraSite 2 platforms are sustained delivery technologies using a synthetic polymer-based formulation designed to extend the residence time of a drug relative to conventional topical therapies. DuraSite and DuraSite 2 enable topical delivery of a solution, gel or suspension and can be customized for delivering a wide variety of potential drug candidates. The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® and Besivance®. InSite Vision is advancing a portfolio of novel preclinical- to clinical-stage ophthalmic products based on the DuraSite platform and anticipates advancing future ophthalmic product candidates using the DuraSite 2 platform.

About InSite Vision

InSite Vision is advancing new ophthalmologic products for unmet eye care needs based on its innovative DuraSite platform technologies. The DuraSite and DuraSite 2 drug delivery systems extend the duration of drug retention on the surface of the eye, thereby reducing the frequency of treatment and improving the efficacy of topical drugs.

The DuraSite platform is currently leveraged in two commercial products for the treatment of bacterial eye infections, AzaSite® (azithromycin ophthalmic solution) 1%, marketed in the U.S. by Merck, and Besivance® (besifloxacin ophthalmic suspension) 0.6%, marketed by Bausch + Lomb. InSite Vision is also advancing three novel ophthalmic therapeutics through Phase 3 clinical studies: AzaSite Plus™ and DexaSite™ for the treatment of eye infections, and BromSite™ for pain and inflammation associated with ocular surgery. For further information on InSite Vision, please visit www.insitevision.com.

AzaSite® and DuraSite® are registered trademarks of InSite Vision Incorporated.
AzaSite Plus™, BromSite™ and DexaSite™ are trademarks of InSite Vision Incorporated.
BESIVANCE® is a registered trademark of Bausch + Lomb Incorporated.



InSite Vision
Louis Drapeau, 510-747-1220
Chief Financial Officer
mail@insite.com
or
Media and Investor inquiries
BCC Partners
Michelle Corral, 415-794-8662
Karen L. Bergman, 650-575-1509

KEYWORDS: United States North America California Washington

INDUSTRY KEYWORDS:

The article InSite Vision to Present Five Scientific Posters at 2013 ARVO Meeting originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Advertisement